UI Research Park

UI Research Park

Comments

For the second year in a row, UI Research Park won the prestigious FAST grant from U.S. Small Business Administration.

It’s a testament to the dedication and innovation shown by the world-class scientists and entrepreneurs that call Illinois home.

https://www.sba.gov/about-sba/sba-newsroom/press-releases-media-advisories/sba-awards-second-125000-grant-university-illinois-incubator-help-underserved-communities-succeed

The UI Research Park provides business incubation, research facilities, and extensive University of Iowa resources to new and established companies.

Operating as usual

Cellular Engineering Technologies (CET) 03/08/2022

Cellular Engineering Technologies (CET)

The USPTO Issues a Patent to Cellular Engineering Technologies For Producing Safer Induced Pluripotent Stem Cells

The patent awards Cellular Engineering Technologies the intellectual property to develop, manufacture and commercialize induced pluripotent stem cells that are virus-free and carry a much lower cancer risk

Coralville, Iowa: Cellular Engineering Technologies (CET), Inc., an Iowa biotechnology company specializing in cell manufacturing and contract research services, today announced that it has received a patent from the United States Patent and Trademark Office for its virus-free and oncogene-free induced pluripotent stem cell (iPSC) technology. The iPSC technology which was previously published in Future Science Open Access and Regenerative Medicine was developed in collaboration with the John Paul II Medical Research Institute (JP2MRI), a non-profit organization. More recently, the National Institutes of Health awarded CET a SBIR grant to commercialize the technology to provide reproducible iPSC and differentiated neural stem cells that maintain pluripotency and genetic stability during large scale production.

The patent provides a new benchmark in pluripotent stem cell safety. Pluripotent stem cells carry an inherent neoplastic risk. Moreover, the industry desire to produce off-the-shelf allogeneic iPSC therapies that are immune-tolerant has the potential for inducing further harm by evading the patient’s innate immune system from unwanted immune-tolerant allogeneic neoplastic cells in a cell therapy. Thus, CET’s patent can realize the full potential of pluripotent stem cells as therapeutic products by reducing the inherent viral and neoplastic risk. This issued patent further strengthens CET’s intellectual property portfolio with its legacy expertise in human somatic stem cell manufacturing and bioprocessing; along with access to a recent worldwide license from ERS Genomics to utilizing CRISPR; and an exclusive license from JP2MRI’s pipeline of immortalized human stem cells that are designed for the bio-production of vaccines, allogeneic cell therapies (including CAR-T and CAR-NK cells), biologics and gene therapy vectors that together provide principled and scientific advantages over the current art. According to Dr. Alan Moy, CEO/CSO and Co-Founder of CET and Founder of JP2MRI, “CET’s objective is to expand contract manufacturing and research services for CET and JP2MRI’s therapeutic pipeline, as well as biopharmaceutical partners who wish to license CET’s pivotal intellectual property to advance their pipeline in cell therapy, biologics, vaccines and gene therapy vectors.”

Contact CET:
Anant Kamath
Chief Operating Officer
Tel: 319-665-3000
Email: [email protected]

About CET www.celleng-tech.com
Cellular Engineering Technologies (CET) is a biotechnology company that specializes in cell manufacturing and contract research services directed towards improving personalized and regenerative medicine. CET has expertise in cellular and tissue engineering, with a key focus on cell manufacturing and tissue culture media optimization, alongside research services that use non-embryonic human cells for less controversial bioprocessing. CET has the largest repository of human somatic stem cells and is the sole source manufacturer of some rare postnatal stem cells. CET employs a first-in-kind induced pluripotent stem cell (iPSC) technology that is virus-free and oncogene-free, with better predictability for drug discovery and safety in cell and gene therapy. CET distributes its products and services in Canada, United States, Asia, and Europe. For additional information please visit: www.celleng-tech.com.

Cellular Engineering Technologies (CET) CET is a biopharmaceutical company with the mission to fundamentally transform personalized medicine like cancer and drug discovery.

11/22/2021

VIDA streamlines respiratory clinical trials with artificial intelligence

November 22, 2021

VIDA Diagnostics, Inc. (VIDA), based in Coralville, has unveiled a new AI-powered portal, further removing friction in respiratory clinical trials.

The cloud-based VIDA Intelligence Portal (VIP) streamlines challenges often associated with imaging in trials such as site onboarding, staff training, image data management, and data quality. Leveraging a powerful AI engine, the portal automates cumbersome and time sensitive tasks such as subject anonymization and quality control workflow processes.

Clinical trial operations are challenging – 80% of trials face delays and 11% of trial sites never enroll a single patient. Respiratory trials that involve imaging are even more difficult due to the complexities involved in proper image acquisition, subject breathing training, image reconstruction, motion artifacts, secure data exchange, and more. VIP allays these issues by automatically applying AI prior to human interaction, allowing for immediate intervention in the event of poor data quality, for example. The result is smoother trials that produce high quality data, leading to more efficient and successful outcomes.

With VIP, available broadly as part of VIDA Discovery, trial sponsors and sites can effortlessly manage scans and related information, eliminating manual steps that often slow trials and can affect data integrity. The highly secure portal serves as a centralized information hub, replacing a patchwork of existing online and offline third-party solutions.

“Our aim is to help sites and sponsors use the power of AI to analyze data for consistency and generate new categories of lung biomarkers. We’re excited to see sites already realizing this promise as well as experiencing more efficient trial imaging operations,” said Todd Johnson, VIDA’s chief technology officer, in a news release. “The VIDA Intelligence Portal also provides a foundation for future innovations we can’t wait to deliver.”

As the leader in respiratory/lung imaging and generation of biomarker insights, VIDA’s rapidly growing clinical data lake is now being leveraged to solve many problems often associated with complex imaging in clinical trials. For example, VIDA’s analysis is helping trial sponsors and sites identify future trial participants or provide access to aggregated data intelligence for future drug studies.

VIDA will demo the portal during the Radiological Society of North America (RSNA) annual meeting, which brings together the world’s leading radiologists and healthcare system executives, Nov. 28 – Dec. 1.

VIDA Streamlines Respiratory Clinical Trials with Artificial Intelligence (AI) 11/18/2021

VIDA Streamlines Respiratory Clinical Trials with Artificial Intelligence (AI)

November 16, 2021

CORALVILLE, Iowa, Nov. 16, 2021 /PRNewswire/ -- VIDA Diagnostics, Inc. (VIDA) is further removing friction in respiratory clinical trials with the introduction of a new AI-powered portal. The cloud-based VIDA Intelligence Portal (VIP) streamlines challenges often associated with imaging in trials such as site onboarding, staff training, image data management, and data quality. Leveraging a powerful AI engine, the portal automates cumbersome and time sensitive tasks such as subject anonymization and quality control workflow processes.

Clinical trial operations are challenging – 80% of trials face delays and 11% of trial sites never enroll a single patient. Respiratory trials that involve imaging are even more difficult due to the complexities involved in proper image acquisition, subject breathing training, image reconstruction, motion artifacts, secure data exchange, and more. VIP allays these issues by automatically applying AI prior to human interaction, allowing for immediate intervention in the event of poor data quality, for example. The result is smoother trials that produce high quality data, leading to more efficient and successful outcomes.
With VIP, available broadly as part of VIDA Discovery, trial sponsors and sites can effortlessly manage scans and related information, eliminating manual steps that often slow trials and can affect data integrity. The highly secure portal serves as a centralized information hub, replacing a patchwork of existing online and offline third-party solutions.

“Our aim is to help sites and sponsors use the power of AI to analyze data for consistency and generate new categories of lung biomarkers. We’re excited to see sites already realizing this promise as well as experiencing more efficient trial imaging operations,” said Todd Johnson, VIDA’s chief technology officer. “The VIDA Intelligence Portal also provides a foundation for future innovations we can’t wait to deliver.”

As the leader in respiratory/lung imaging and generation of biomarker insights, VIDA’s rapidly growing clinical data lake is now being leveraged to solve many problems often associated with complex imaging in clinical trials. For example, VIDA’s analysis is helping trial sponsors and sites identify future trial participants or provide access to aggregated data intelligence for future drug studies.

VIDA will demo the portal during the Radiological Society of North America (RSNA) annual meeting, which brings together the world’s leading radiologists and healthcare system executives, November 28 – December 1, at Booth #4351. CTO Todd Johnson will speak on Tuesday, November 30 at 12 noon CST as part of the AI Showcase about the role the portal plays in improving clinical trial and AI ROI. To schedule a briefing, email [email protected].

About VIDA Diagnostics

VIDA quantifies imaging biomarkers of lung diseases to provide clear, measurable evidence that accelerates the therapy pipeline and empowers precise diagnoses and treatments to advance lung care. Through quantitative data intelligence and impactful visualizations, VIDA helps physicians manage patients with or at risk of chronic obstructive pulmonary disease (COPD), interstitial lung disease, asthma, emphysema, lung cancer, and COVID-19. VIDA’s software is FDA cleared, CE-marked, Health Canada licensed and TGA registered for clinical use in the US, European Economic Area, Canada, and Australia. Learn more at https://vidalung.ai/. Follow @vidalung on Twitter and LinkedIn.

View original content to download multimedia: https://www.prnewswire.com/news-releases/vida-streamlines-respiratory-clinical-trials-with-artificial-intelligence-ai-301425469.html

VIDA Streamlines Respiratory Clinical Trials with Artificial Intelligence (AI) /PRNewswire/ -- VIDA Diagnostics, Inc. (VIDA) is further removing friction in respiratory clinical trials with the introduction of a new AI-powered portal. The...

Timeline photos 11/04/2021

Check it out.

Voxello and the noddle system have been featured by the NIH in it's NINR Research Highlights. Check it out: https://bit.ly/3pY7Iys

10/06/2021

Congratulations Adam, Alec and Ben!

Congratulations Adam, Alec, and Ben!

“People around the world are using smartphones and if we put engaging learning materials on it, we can help people learn through that.”

Learn more about HLT ➭ https://bit.ly/2Yhh8cL

10/06/2021

Congratulations!

Congratulations Michael and Frances!

“Often when you work for a long time to get something done, you are recognized more from afar than you are at home."

Read more about Viewpoint Molecular Targeting➭ https://bit.ly/3mmbQok

09/09/2021

Viewpoint Molecular Targeting™ Receives FDA Clearance of Investigational New Drug Application for Phase 1 Imaging Study for VMT-a-NET for Neuroendocrine Tumors

September 9, 2021
Coralville, IA, September 9, 2021 – Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug application (IND) to commence a Phase 1 imaging study of VMT-a-NET for imaging of neuroendocrine tumors (NETs). The Phase 1 imaging study is an investigator-initiated study that will be conducted at the University of Iowa Hospitals and Clinics.

The Phase 1 imaging study will evaluate [ 203Pb]VMT-a-NET as an agent for imaging somatostatin receptor subtype 2 (SSTR2)-positive neuroendocrine tumors. The images obtained will inform future therapeutic trials of [212Pb]VMT-a-NET alpha-particle therapy for this tumor type. In parallel to this investigator initiated imaging trial, the Company plans to move forward with a Phase 1/2a therapy study of VMT-a-NET for the treatment of neuroendocrine tumors.

“We are incredibly pleased that our second product has received IND clearance from the FDA, allowing our collaborators at the University of Iowa to proceed with another first-in-human Phase 1 imaging study. We continue to be encouraged by the preclinical results demonstrated to date, that show the promise of treating this disease with targeted alpha-particle therapy. With this milestone now achieved, Viewpoint together with the team at the University of Iowa is excited to progress toward enrollment and provisional results in our imaging study over the remainder of this year,” commented Frances L. Johnson, MD, Chief Executive Officer and Co-Founder of Viewpoint Molecular Targeting.

Preclinical data seen to-date provides strong evidence that the VMT-a-NET image-guided approach can be an effective therapy with a promising toxicity profile. Supported by over $4 million in the form of Small Business Innovation Research grants and R01 academic research grants from the NCI to advance this treatment, VMT-a-NET is well-positioned to apply the new transformative power of alpha-particle treatment to NET tumors and other cancers that express the SST2R biomarker.

Neuroendocrine tumors are rare forms of cancers that occur most commonly in the pancreas or other areas of the gut such as the stomach, small intestine, rectum, colon, or appendix. A neuroendocrine tumor may grow slowly or aggressively and spread to other parts of the body. Diagnosis and treatment of neuroendocrine tumors depend on the type of tumor, its location, whether it produces excess hormones, how aggressive it is and whether it has spread to other parts of the body. Some approaches may include surgery, radiation, and chemotherapy.

About Viewpoint:

Viewpoint Molecular Targeting is a radiopharmaceutical company developing precision oncology therapeutics and complementary diagnostic imaging agents. The Company’s proprietary technology utilizes lead-212 to deliver powerful alpha radiation specifically to cancer cells via specialized targeting peptides. Viewpoint is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic” approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments. The Company’s melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs are entering Phase 1 imaging studies, to be followed by Phase 1/2a therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at two leading academic institutions. The Company has also developed a proprietary lead-212 generator to secure isotope supply for clinical trial and commercial operations. For more information, please visit the Company’s website viewpointmt.com.

Investor Inquiries:

Jenene Thomas,
Chief Executive Officer JTC Team, LLC

T: 833.475.8247

[email protected]

Telephone

Address


2500 Crosspark Rd
Coralville, IA
52241

Opening Hours

Monday 8am - 5pm
Tuesday 8am - 5pm
Wednesday 8am - 5pm
Thursday 8am - 5pm
Friday 8am - 5pm

Other Medical & Health in Coralville (show all)
Gheko Health Gheko Health
Coralville, 52241

Decolletage Perfect Fit Boutique Decolletage Perfect Fit Boutique
Coralville, 52241

Recently closed. Visit https://www.facebook.com/scarletcustom/ (located just upstairs from previous location) for your post-mastectomy needs.

BPR Therapy, Mediation and Coaching Services BPR Therapy, Mediation and Coaching Services
2441 Coral Court
Coralville, 52241

CIVCO Medical Solutions CIVCO Medical Solutions
2301 Jones Blvd
Coralville, 52241

CIVCO's mission is to make ultrasound-guided procedures safer with solutions for ultrasound probe high-level disinfection, infection control, and needle guidance.

Beltone Hearing Beltone Hearing
1150 5th St Ste 276
Coralville, 52241

With 1,500 locations nationwide, we are here to support you on your journey to better hearing and lend our expertise as you choose the best hearing aids for your unique needs and lifestyle.

Light Awake Light Awake
Coralville, 52241

Alarm clock app for a cell phone or tablet. Uses light to wake people up.